AETHLON MEDICAL INC

Listed Company

AEMDCIK 0000882291NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusNevadaFY ends Mar 31

Period

FY 2025

Revenue

—

Net Income

$-13.39M

Total Assets

$7.36M

Equity

$5.12M

Shares Out

1.32M

Op. Cash Flow

$-7.65M

Business

AETHLON MEDICAL INC is a medical therapeutic company developing the Hemopurifier®, a clinical‑stage lectin‑affinity extracorporeal device designed to remove harmful extracellular vesicles and enveloped viruses from plasma. Its main product offering is the Hemopurifier treatment platform used in plasmapheresis sessions to capture pathogenic viruses and EVs implicated in cancer progression, severe viral infections and transplant contexts. Key business activities are organized around oncology clinical programs, life‑threatening viral infection applications and ongoing R&D and manufacturing support. Clinical development and distribution occur through hospitals and clinical trial sites in the United States, Australia, India and other international research collaborations.

Summary from filing dated 2025-06-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Professional fees	2	4	4	3	3
Payroll and related expenses	4	5	4	5	3
General and administrative	3	4	4	3	2
Total operating expenses	9	13	12	11	9
OPERATING LOSS	−9	−13	−12	−10	−8
Interest income	−298,122	−447,356	—	—	—
Other income	−324,450	0	—	—	—
Interest expense	10,109	—	—	—	—
Other expense	5	18,962	—	—	—
Total other expense (income), net	4	−428,394	131,148	0	—
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	−13	−12	−12	−10	−8
Basic loss per share attributable to common stockholders	−8.58	−38.87	−5.86	−0.71	—
Diluted loss per share attributable to common stockholders	−8.58	−38.87	−5.86	−0.71	—
Weighted average number of common shares outstanding - basic	2	314,097	2	15	—
Weighted average number of common shares outstanding - diluted	2	314,097	2	15	—
OTHER COMPREHENSIVE LOSS	−10,193	−799	—	—	—
COMPREHENSIVE LOSS	−13	−12	−12	−10	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Cash and cash equivalents	6	5	15	17	—
Deferred offering costs	0	277,827	0	—	—
Prepaid expenses and other current assets	448,539	505,983	557,623	956,623	341,081
TOTAL CURRENT ASSETS	6	6	15	18	10
Property and equipment, net	676,220	1	1	441,238	160,976
Operating lease right-of-use asset	601,846	883,054	1	696,698	40,363
Patents, net	550	1,100	1,650	2,200	56,954
Restricted cash	97,813	87,506	87,506	87,506	46,726
Deposits	33,305	33,305	33,305	33,305	12,159
TOTAL ASSETS	7	8	18	19	11
Accounts payable	534,524	777,862	432,889	499,962	337,678
Due to related parties	579,565	546,434	214,221	—	—
Operating lease liability, current portion	313,033	290,565	269,386	126,905	42,543
Other current liabilities	472,164	215,038	588,592	696,893	761,636
TOTAL CURRENT LIABILITIES	2	2	2	2	1
Operating lease liability, less current portion	336,718	649,751	939,642	602,505	0
TOTAL LIABILITIES	2	2	2	2	1
COMMITMENTS AND CONTINGENCIES (Note 8)	—	—	—	—	—
Common stock, $0.001 par value, 60,000,000 shares authorized at March 31, 2025 and 2024; 2,585,239 and 328,728 shares issued and 2,010,739 and 328,728 outstanding at March 31, 2025 and 2024, respectively	2,586	329	2,299	15,421	12,152
Additional paid-in capital	173	160	157	147	129
Accumulated other comprehensive loss	−17,133	−6,940	−6,141	0	—
Accumulated deficit	−168	−155	−142	−130	−120
TOTAL STOCKHOLDERS EQUITY	5	6	15	17	9
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	7	8	18	19	11

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Depreciation and amortization	339,559	359,057	240,892	123,685	39,939
Stock-based compensation	415,234	1	1	750,621	779,421
Loss on disposal of property, plant and equipment	0	21,135	0	—	—
Non-cash lease expense	281,208	143	24,408	—	—
Warrant Inducement Expense	5	0	—	—	—
Prepaid expenses and other current assets	113,923	−10,232	398,169	−636,688	−111,477
Accounts payable and other current liabilities	−53,360	156,678	−174,727	97,541	341,858
Due to related parties	33,131	332,213	58,479	37,222	6,813
Net cash used in operating activities	−8	−10	−11	−10	−7
Purchases of property and equipment	0	−250,867	−943,109	−349,193	−59,881
Cash used in investing activities	0	−250,867	−943,109	−349,193	−59,881
Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units	−18,927	−34,778	−12,493	−88,118	−132,527
Net proceeds from the issuance of common stock	4	1	9	—	—
Proceeds from exercise of warrants standard terms	2	0	—	—	—
Proceeds from exercise of warrants induced terms	2	0	—	—	—
Commission paid related to warrant inducement	−153,979	0	—	—	—
Legal fees paid related to warrant inducement	−10,877	0	—	—	—
Net cash provided by financing activities	8	1	9	17	7
Effect of Exchange Rate on Changes on Cash	−12,262	2,107	−5,957	0	—
Net increase (decrease) in cash and cash equivalents and restricted cash	69,590	−9	−3	7	—
Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services	13	35	92	44	98
Disposal of fully depreciated property	350,670	0	—	—	—
Reversal of accrued commission liability (see Note 6)	0	404,120	—	—	—
Deferred offering costs not yet paid	0	219,117	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro